$MRK Ridgeback Bio's Ph 2 antiviral COVID candidate results and potential initiation of larger trials, 2 $BMY CheckMate 9ER (Opdivo + Cabometyx vs. Sutent) Phase 3 1L renal cancer detailed data – especially safety&amp;subgroups (PFS/OS  on 4/20/20) to compare to KN-426 cross-trial,